Lilly allies with BioArctic; Antengene and Insilico sign dealsnews2026-06-22T15:07:19+00:00June 22nd, 2026|Endpoints News|
Pfizer CFO to depart; GSK wins approval for UTI drugnews2026-06-18T14:54:51+00:00June 18th, 2026|Endpoints News|
Lilly buys another pain biotech; FDA sets decision for once-weekly PrEP pillnews2026-06-16T14:22:47+00:00June 16th, 2026|Endpoints News|
Gan & Lee’s Phase 3 obesity successes; J&J touts multiple myeloma datanews2026-06-15T15:23:38+00:00June 15th, 2026|Endpoints News|
Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory studynews2026-06-12T14:52:26+00:00June 12th, 2026|Endpoints News|
Sensorion axes hearing loss program; Novartis’ biomarker data in muscular dystrophynews2026-06-11T14:48:47+00:00June 11th, 2026|Endpoints News|
Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundationnews2026-06-10T14:01:21+00:00June 10th, 2026|Endpoints News|
Lilly offers up to $1B for Alzheimer’s drug; Bial cuts failed Parkinson’s drugnews2026-06-09T14:37:24+00:00June 9th, 2026|Endpoints News|
GSK inks multi-target pact with Engitix; Sangamo considers strategic optionsnews2026-06-08T14:17:48+00:00June 8th, 2026|Endpoints News|
Fulcrum lays off majority of staff; Seres extends runway into 2027news2026-06-05T12:55:14+00:00June 5th, 2026|Endpoints News|
